Heart failure & cardiomyopathiesRandomised controlled trial
Cost-effectiveness of finerenone in heart failure with mildly reduced or preserved ejection fraction: Insights from FINEARTS-HF
- Cost-effectiveness analysis of the FINEARTS-HF randomised trial
- cohort-based Markov model
- deterministic and probabilistic sensitivity analysis
Authors' conclusion
In patients with HFmrEF/HFpEF, finerenone was not cost-effective over the trial horizon at U.S. pricing but demonstrated favourable economic value under German pricing.
Study context
- Population
- Patients with HFmrEF/HFpEF, United States (US) health care sector and German statutory health insurance (GKV) perspectivesFINEARTS-HF data
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo
- Primary endpoint
- ICER (cost per QALY), in-trial and lifetime
- Follow-up
- 32 months (in-trial) and lifetime
Primary result
As reported in the abstract
In-trial cost-effectiveness (ICER) of finerenone · 32 months
- US in-trial incremental cost-effectiveness ratio (ICER) per QALY
- $473,000
- US probability of cost-effectiveness at $100,000 per QALY
- <5%
- German in-trial ICER per QALY
- €47,800
- German probability of cost-effectiveness at €30,000 per QALY
- 41%
- German probability of cost-effectiveness at €50,000 per QALY
- 63%
Further findings
Lifetime cost-effectiveness · lifetime horizon
- Discounted quality-adjusted life-years (QALYs) with finerenone vs comparator
- 7.44 vs. 6.98
- US lifetime ICER per QALY
- $54,000
- Germany lifetime
- cost-saving
- Probability of cost-effectiveness
- >95%
Original publication
Cost-effectiveness of finerenone in heart failure with mildly reduced or preserved ejection fraction: Insights from FINEARTS-HF. Eur J Heart Fail. Published 24 May 2026. doi:10.1093/ejhf/xuag167
Summarised from the published abstract; every number is checked against it